GLP-1 receptor agonists are among the most expensive drugs in the US pharmacy system. Ozempic (semaglutide 0.5 mg to 2 mg, for type 2 diabetes) lists at roughly $935 per month. Wegovy (semaglutide 2.4 mg, for weight management) lists at around $1,350 per month. Zepbound (tirzepatide, for weight management) runs $1,060 to $1,080 per month. Without insurance, these are effectively out of reach at sticker price.
The good news: there are multiple paths to pay far less. Manufacturer cash-pay programs, manufacturer patient assistance programs for low-income patients, Medicare's new GLP-1 Bridge (starting July 1, 2026), and compounded alternatives (where legally available) can reduce monthly costs dramatically. This guide covers each option, what it costs, and who qualifies as of 2026.
Note on compounded GLP-1s: The FDA resolved the semaglutide shortage in February 2025, ending large-scale compounding by 503B outsourcing facilities (deadline May 22, 2025). Some 503A pharmacies can still compound semaglutide for individual patients with a valid prescription. Tirzepatide remains on the FDA shortage list as of spring 2026, so compounded tirzepatide from licensed pharmacies remains legally available. Compounded formulations are not FDA-approved, carry different safety profiles, and should only be obtained through a licensed compounding pharmacy with a physician prescription.
What GLP-1 Without Insurance Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same glp-1 without insurance can cost many times more at a hospital than at your local pharmacy:
2026 GLP-1 Without Insurance Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Retail pharmacy (no insurance, brand name) | $900 - $1,300/month | Ozempic ~$935, Wegovy ~$1,350, Zepbound ~$1,060 list price |
| Manufacturer direct cash-pay programs | $149 - $549/month | LillyDirect Zepbound vials $299-$549; NovoCare Ozempic $199-$499; Wegovy self-pay $199-$399 |
| Compounded semaglutide or tirzepatide (telehealth) | $129 - $399/month | Tirzepatide compounding still legal (shortage list). Semaglutide compounding restricted since May 2025. |
| Medicare Part D (GLP-1 Bridge, starting July 1, 2026) | $50/month | Wegovy and Zepbound only, for Medicare weight-management coverage |
| Medicaid | $1 - $10/prescription | Coverage and formulary vary by state; type 2 diabetes indication more consistently covered |
Retail prices sourced from GoodRx and manufacturer websites. Direct cash-pay prices current as of May 2026 and subject to change. Compounding availability subject to FDA shortage list status.
Source: GoodRx, LillyDirect, NovoCare, FDA Drug Shortage List 2026
Why Hospitals Charge So Much
GLP-1 drugs are primarily self-administered outpatient medications, so hospital markups are less common than with inpatient infusion drugs. However, patients who receive these drugs during an inpatient stay or in a clinical setting can face facility markups on top of an already high list price. Because GLP-1 injectables are Part D drugs (not Part B), hospitals cannot bill Medicare directly for them the same way they would for infused biologics. Charges you see on a hospital bill are based on the hospital's Charge Description Master (CDM) -- a proprietary price list that bears little relationship to acquisition cost.
The larger affordability problem for GLP-1 drugs is not the hospital bill: it is the ongoing monthly out-of-pocket cost for insured and uninsured patients alike. Most commercial health plans exclude GLP-1 drugs for weight management even when they cover the same drugs for type 2 diabetes. This coverage split is why the out-of-pocket cost question dominates GLP-1 access -- and why manufacturer direct programs and compounding became so widely used.
Under the Inflation Reduction Act of 2022, CMS negotiated prices on the first ten high-cost drugs effective January 2026. Ozempic, Wegovy, and Zepbound were not among those first ten, so they have not been directly subject to IRA Maximum Fair Price caps yet. However, CMS has begun expanding Medicare coverage of GLP-1s for cardiovascular risk reduction and obesity, creating new pathways that will affect pricing dynamics through 2026 and beyond.
Patient Assistance Programs
Several manufacturer programs can reduce GLP-1 costs significantly. Eligibility, covered drugs, and income thresholds differ by manufacturer and by whether the drug is prescribed for diabetes or weight management:
Patient assistance programs for GLP-1 Without Insurance| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Novo Nordisk Patient Assistance Program (NovoCare) | Free Ozempic if income at or below 200% FPL; other Novo Nordisk drugs at or below 400% FPL. Must be uninsured or on Medicare (no private insurance). Wegovy not covered by PAP. | novocare.com |
| LillyDirect Cash-Pay (Zepbound and Mounjaro) | Zepbound single-dose vials $299 (2.5 mg, 5 mg) to $549/month at higher doses. No income limit -- open to anyone paying cash. Mounjaro for diabetes also available. | lillydirect.com |
| Lilly Cares Foundation (Mounjaro for type 2 diabetes only) | Free Mounjaro for qualifying low-income, uninsured or underinsured patients. Income thresholds 300-500% FPL depending on medication group. Zepbound not covered. | lillycares.com |
| Wegovy Self-Pay Direct (NovoCare Pharmacy) | $199/month for first two fills (0.25 mg, 0.5 mg starter doses) through June 30, 2026. After that, $349/month for all maintenance doses up to 2.4 mg. | wegovy.com |
Medicare beneficiaries are no longer eligible for Novo Nordisk PAP as of 2026. Savings cards (e.g., Zepbound $25 copay card) require commercial insurance and are not available to Medicare or Medicaid enrollees. Verify current eligibility at manufacturer websites before applying.
Source: NovoCare.com, LillyDirect.com, LillyCares.com, NeedyMeds.org
Medicare Part D
GLP-1 drugs prescribed for type 2 diabetes (Ozempic, Mounjaro) are generally covered by Medicare Part D plans, subject to formulary tier and plan deductible. The 2026 Part D annual out-of-pocket cap is $2,100 -- once you hit that, you pay nothing for covered drugs for the rest of the year. GLP-1 drugs prescribed solely for weight management were historically excluded from Medicare Part D formularies under a statutory exclusion for 'agents when used for weight loss.'
Starting July 1, 2026, CMS introduced the Medicare GLP-1 Bridge, a new pathway giving eligible Medicare Part D beneficiaries access to Wegovy (semaglutide injection and tablet) and Zepbound (tirzepatide KwikPen) for weight management at a capped $50 per month copay. This covers the drugs' cardiovascular risk-reduction indication. Not all Part D plans are participating yet -- check your specific plan's formulary for the July 2026 update.
For Medicare beneficiaries with type 2 diabetes, Ozempic is covered by most Part D plans and was negotiated down to an IRA Maximum Fair Price of $197 for a 30-day supply effective 2026. If you have Medicare and need a GLP-1 for diabetes, call your plan to confirm Ozempic or Mounjaro is on your formulary before filling.
Common GLP-1 Without Insurance Billing Errors
GLP-1 drug billing errors occur most often when a drug prescribed for one indication (weight loss) is coded for another (diabetes) or vice versa. They also arise from confusion between brand-name and compounded products:
- Ozempic billed with a weight-management diagnosis code (ICD-10 E66) instead of diabetes (E11) -- triggers denial from most plans
- Compounded semaglutide billed as brand-name Ozempic or Wegovy -- these are not equivalent and insurers will not pay brand rate for a compounded product
- Insurance claim filed for Wegovy when plan excludes weight-loss agents -- should use manufacturer direct-pay program instead of submitting to insurance
- Wrong drug or dose billed when starter dose titration schedule was changed mid-prescription
- Duplicate fill charges from telehealth platform and retail pharmacy when prescription was sent to both
Frequently Asked Questions
What is the cheapest way to get GLP-1 medications without insurance in 2026?
The lowest-cost legal options in 2026 are: (1) LillyDirect Zepbound single-dose vials starting at $299 per month (no income requirement); (2) NovoCare Pharmacy Wegovy self-pay at $199 per month for the first two starter fills; (3) compounded tirzepatide from a licensed 503A pharmacy starting around $129 to $299 per month (tirzepatide remains on the FDA shortage list, making compounding still legal). Low-income uninsured patients may qualify for free Ozempic through the Novo Nordisk PAP at 200% FPL or under.
Can I still get compounded semaglutide in 2026?
Large-scale 503B outsourcing compounding of semaglutide ended May 22, 2025, after the FDA resolved the shortage. Some 503A compounding pharmacies can still compound semaglutide for individual patients with a valid prescription, but availability is limited and varies by state. Compounded tirzepatide remains more widely available because tirzepatide is still on the FDA shortage list as of spring 2026. Always verify a pharmacy's 503A license before purchasing compounded GLP-1 products.
Does Medicare cover Ozempic or Wegovy in 2026?
Ozempic (for type 2 diabetes) is covered by most Medicare Part D plans. Starting July 1, 2026, Medicare beneficiaries can access Wegovy and Zepbound for weight management through the Medicare GLP-1 Bridge at a $50 per month copay. Before July 2026, Wegovy and Zepbound were excluded from Medicare Part D for weight-management indications. The 2026 Part D annual out-of-pocket cap is $2,100 -- once reached, covered drugs cost nothing for the rest of the year.
What income qualifies for the Novo Nordisk free Ozempic program?
The Novo Nordisk Patient Assistance Program provides free Ozempic to uninsured patients with household income at or below 200% of the federal poverty level -- approximately $29,160 for a single person in 2026. For other Novo Nordisk diabetes medications, the limit is 400% FPL. Patients with private insurance do not qualify for the PAP. Wegovy is not covered by the Novo Nordisk PAP. Apply at novocare.com or call 1-866-310-7549.
Is LillyDirect a patient assistance program or just direct pricing?
LillyDirect is Eli Lilly's direct-to-consumer pharmacy program -- it offers lower cash-pay prices but is not a patient assistance program based on income. As of 2026, Zepbound single-dose vials are sold through LillyDirect at $299 per month (2.5 mg and 5 mg) to $549 per month at higher doses. There is no income requirement. The separate Lilly Cares Foundation PAP covers Mounjaro (for type 2 diabetes) at no cost for qualifying low-income patients, but Zepbound is not included in Lilly Cares.
Why does my insurance cover Ozempic for diabetes but not Wegovy for weight loss?
Ozempic and Wegovy both contain semaglutide but are FDA-approved for different indications. Ozempic is approved for type 2 diabetes and often covered by commercial and Medicare Part D plans. Wegovy is approved for weight management and was historically excluded from most commercial plans and all Medicare Part D plans under a statutory exclusion for weight-loss agents. Coverage is improving in 2026, but most commercial plans still exclude weight-management GLP-1s. Check your plan's Summary of Benefits before assuming coverage.
How safe are compounded GLP-1 drugs compared to brand-name versions?
Brand-name GLP-1 drugs (Ozempic, Wegovy, Zepbound, Mounjaro) go through full FDA approval, including standardized dosing, manufacturing controls, and post-market surveillance. Compounded versions are not FDA-approved and are not equivalent. As of early 2025, the FDA received over 455 adverse event reports linked to compounded semaglutide, many from dosing errors due to patients self-administering from multidose vials. If using a compounded product, only use one dispensed by a licensed 503A pharmacy with a valid prescription and follow dosing instructions exactly.
What happens to my GLP-1 cost if I hit the Part D $2,100 out-of-pocket cap?
Under the 2026 Medicare Part D redesign, once you spend $2,100 in out-of-pocket costs on covered drugs during the calendar year, you pay $0 for the rest of the year. This cap replaced the old 'donut hole' structure. GLP-1 drugs for type 2 diabetes (Ozempic, Mounjaro) are typically Part D-covered and count toward this cap. If your GLP-1 is your highest-cost drug, you may hit the cap mid-year and pay nothing for the remainder.
